| Autor: |
Richterman A; Division of Infectious Diseases, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.; Penn Leonard Davis Institute of Health Economics, Philadelphia, PA, USA., O'Brien C; Mixed Methods Research Laboratory, University of Pennsylvania, Philadelphia, PA, USA., Ghadimi F; Division of Infectious Diseases, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Sumners E; The COLOURS Organization, Philadelphia, PA, USA., Ford A; The COLOURS Organization, Philadelphia, PA, USA., Houston N; Bebashi-Transition to Hope, Philadelphia, PA, USA., Tate S; Bebashi-Transition to Hope, Philadelphia, PA, USA., Aitcheson N; Division of Infectious Diseases, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.; Penn Leonard Davis Institute of Health Economics, Philadelphia, PA, USA., Nkwihoreze H; Division of Infectious Diseases, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Jemmott JB 3rd; Annenberg School of Communication, University of Pennsylvania, Philadelphia, PA, USA.; Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA., Momplaisir F; Division of Infectious Diseases, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.; Penn Leonard Davis Institute of Health Economics, Philadelphia, PA, USA. |
| Abstrakt: |
Little is known about the pre-implementation context for a preventive HIV vaccine. We conducted interviews of individuals in Philadelphia recruited at Penn clinics and community-based organizations serving LGBTQ-identifying persons of color who 1) were cisgender men who had sex with men, or were transgender-identified, 2) had a sexually transmitted infection in the last 12 months, or sex with multiple partners within the last two weeks. We assessed acceptability, facilitators, and barriers to a hypothetical HIV vaccine using an integrated analysis approach. We interviewed 30 individuals between 2/2023-9/2023. Participants were supportive of an HIV vaccine and reported that they would strongly consider receiving one if one became available. Participants contextualized a hypothetical vaccine with the current HIV prevention context, primarily pre-exposure prophylaxis (PrEP), indicating that they would evaluate any future vaccine in comparison to their experience within the PrEP landscape.Reported facilitators for a hypothetical HIV vaccine included vaccine access, knowledge, and understanding; their risk for HIV exposure; and perceived benefits of the vaccine. Barriers included lack of understanding of the purpose of a vaccine, stigma surrounding HIV and sexual practices that may surface towards people who seek vaccination, and potential issues with effectiveness, side effects, or lack of availability. |
